Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Cardiff Oncology Inc (CRDF)

Cardiff Oncology Inc (CRDF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Cardiff Oncology Inc 11055 FLINTKOTE AVENUE SAN DIEGO CA 92121 USA

https://cardiffoncology.com Employees: 32 P: 858-952-7570 F: 858-952-7571

Description:

Cardiff Oncology Inc. is a clinical-stage biotechnology company. It engages in developing treatment for cancer patients. The company's product pipeline consists of a Phase 1b/2 study of onvansertib in combination with FOLFIRI/Avastin(R) in KRAS-mutated metastatic colorectal cancer; a Phase 2 study of onvansertib in combination with Zytiga(R) in Zytiga-resistant metastatic castration-resistant prostate cancer; and a Phase 2 study of onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia. Cardiff Oncology Inc., formerly known as Trovagene Inc., is based in SAN DIEGO.

Key Statistics

Overview:

Market Capitalization, $K 217,831
Enterprise Value, $K 196,171
Shares Outstanding, K 51,134
Annual Sales, $ 490 K
Annual Net Income, $ -41,440 K
Last Quarter Sales, $ 170 K
Last Quarter Net Income, $ -11,860 K
EBIT, $ -46,410 K
EBITDA, $ -46,930 K
60-Month Beta 1.89
% of Insider Shareholders 7.80%
% of Institutional Shareholders 16.29%
Float, K 47,146
% Float 92.20%
Short Volume Ratio 0.43

Growth:

1-Year Return 195.83%
3-Year Return -33.95%
5-Year Return 232.81%
5-Year Revenue Growth 28.95%
5-Year Earnings Growth 88.74%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.25 on 11/07/24
Next Earnings Date N/A
Earnings Per Share ttm -0.94
EPS Growth vs. Prev Qtr 3.85%
EPS Growth vs. Prev Year -13.64%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-6 on 02/20/19

CRDF Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -73.97%
Return-on-Assets % -60.40%
Profit Margin % -8,457.14%
Debt/Equity 0.00
Price/Sales 470.47
Price/Cash Flow N/A
Price/Book 4.23
Book Value/Share 1.06
Interest Coverage -2.18
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar